Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer
Advanced Science · 2023-09 · 10 (25)
DOI: 10.1002/advs.202301088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 10.07.2023. Verfasst von Kaixuan Zeng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medical Research Institute, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710000, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Ferroptosis. Die Arbeit wurde bisher 164-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Basic Research Program of Shaanxi Province, Shaanxi Provincial Health Research Fund.
Abstract (Originalsprache)
Oxaliplatin is a widely used chemotherapy drug for patients with advanced colorectal cancer (CRC); however, frequent drug resistance limits its therapeutic efficacy in patients. Here, this work identifies cyclin‐dependent kinase 1 ( CDK1 ) as a critical contributor to oxaliplatin resistance via in vitro and in vivo CRISPR/Cas9 screening. CDK1 is highly expressed in oxaliplatin‐resistant cells and tissues due to the loss of N6‐methyladenosine modification. Genetic and pharmacological blockade of CDK1 restore the susceptibility of CRC cells to oxaliplatin in vitro and in cell/patient‐derived xenograft models. Mechanistically, CDK1 directly binds to and phosphorylates Acyl‐CoA synthetase long‐chain family 4 (ACSL4) at S447, followed by recruitment of E3 ubiquitin ligase UBR5 and polyubiquitination of ACSL4 at K388, K498, and K690, which leads to ACSL4 protein degradation. Reduced ACSL4 subsequently blocks the biosynthesis of polyunsaturated fatty acid containing lipids, thereby inhibiting lipid peroxidation and ferroptosis, a unique iron‐dependent form of oxidative cell death. Moreover, treatment with a ferroptosis inhibitor nullifies the enhancement of CRC cell sensitivity to oxaliplatin by CDK1 blockade in vitro and in vivo. Collectively, the findings indicate that CDK1 confers oxaliplatin resistance to cells by suppressing ferroptosis. Therefore, administration of a CDK1 inhibitor may be an attractive strategy to treat patients with oxaliplatin‐resistant CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Medical Research Institute, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710000, China.
- Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
- Department of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
- IIT Project Management Office, the First Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.
ORCID-Profile: Chi Zhou
Förderung
- National Natural Science Foundation of China
- Natural Science Basic Research Program of Shaanxi Province
- Shaanxi Provincial Health Research Fund
- China Postdoctoral Science Foundation
- Guangdong Basic and Applied Basic Research Foundation
- Medical Scientific Research Foundation of Guangdong Province
- Fundamental Research Funds for the Central Universities
- Free Exploration and Innovation Fund
Zitieren
APA
Zeng, K., Li, W., Wang, Y., Zhang, Z., Zhang, L., Zhang, W., Xing, Y., & Zhou, C. (2023). Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer. Advanced Science, 10(25). https://doi.org/10.1002/advs.202301088
Vancouver
Zeng K, Li W, Wang Y, Zhang Z, Zhang L, Zhang W, et al. Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer. Advanced Science. 2023;10(25). doi:10.1002/advs.202301088
BibTeX
@article{Zeng2023,
author = {Zeng, Kaixuan and Li, Weihao and Wang, Yue and Zhang, Zifei and Zhang, Linjie and Zhang, Weili and Xing, Yue and Zhou, Chi},
title = {Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer},
journal = {Advanced Science},
year = {2023},
volume = {10},
number = {25},
doi = {10.1002/advs.202301088}
}
EUVIMED